Article ; Online: From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for
2019 Volume 24, Issue 6, Page(s) e318–e326
Abstract: Introduction: Gefitinib, erlotinib, and afatinib represent the approved first-line options for epidermal growth factor receptor (: Methods: MOST is a multicenter observational study promoted by the Veneto Oncology Network, aiming at monitoring the ... ...
| Abstract | Introduction: Gefitinib, erlotinib, and afatinib represent the approved first-line options for epidermal growth factor receptor ( Methods: MOST is a multicenter observational study promoted by the Veneto Oncology Network, aiming at monitoring the diagnostic-therapeutic pathway of patients with nonsquamous Results: An Conclusion: Good regional adherence and compliance to the diagnostic-therapeutic pathway defined for patients with nonsquamous NSCLC was shown. mTTF did not significantly differ among the three targeted TKIs. Our budget impact analysis suggests the potential application of real-world data in the process of drug price negotiation. Implications for practice: The MOST study is a real-world data collection reporting a multicenter adherence and compliance to diagnostic-therapeutic pathways defined for patients with epidermal growth factor receptor-mutant non-small cell lung cancer. This represents an essential element of evidence-based medicine, providing information on patients and situations that may be challenging to assess using only data from randomized controlled trials, e.g., turn-around time of diagnostic tests, treatment compliance and persistence, guideline adherence, challenging-to-treat populations, drug safety, comparative effectiveness, and cost effectiveness. This study may be of interest to various stakeholders (patients, clinicians, and payers), providing a meaningful picture of the value of a given therapy in routine clinical practice. |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MeSH term(s) | Adult ; Afatinib/economics ; Afatinib/therapeutic use ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/economics ; Carcinoma, Non-Small-Cell Lung/genetics ; Cost-Benefit Analysis ; Critical Pathways/standards ; Critical Pathways/statistics & numerical data ; DNA Mutational Analysis/standards ; DNA Mutational Analysis/statistics & numerical data ; Disease Progression ; Disease-Free Survival ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/genetics ; Erlotinib Hydrochloride/economics ; Erlotinib Hydrochloride/therapeutic use ; Female ; Follow-Up Studies ; Gefitinib/economics ; Gefitinib/therapeutic use ; Guideline Adherence/standards ; Humans ; Lung Neoplasms/diagnosis ; Lung Neoplasms/drug therapy ; Lung Neoplasms/economics ; Lung Neoplasms/genetics ; Male ; Medication Adherence/statistics & numerical data ; Middle Aged ; Mutation ; Practice Guidelines as Topic ; Progression-Free Survival ; Prospective Studies ; Protein Kinase Inhibitors/economics ; Protein Kinase Inhibitors/therapeutic use ; Time Factors ; Treatment Failure | ||||||||||
| Chemical Substances | Protein Kinase Inhibitors ; Afatinib (41UD74L59M) ; Erlotinib Hydrochloride (DA87705X9K) ; EGFR protein, human (EC 2.7.10.1) ; ErbB Receptors (EC 2.7.10.1) ; Gefitinib (S65743JHBS) | ||||||||||
| Language | English | ||||||||||
| Publishing date | 2019-03-07 | ||||||||||
| Publishing country | United States | ||||||||||
| Document type | Journal Article ; Multicenter Study ; Observational Study ; Research Support, Non-U.S. Gov't | ||||||||||
| ZDB-ID | 1409038-7 | ||||||||||
| ISSN | 1549-490X ; 1083-7159 | ||||||||||
| ISSN (online) | 1549-490X | ||||||||||
| ISSN | 1083-7159 | ||||||||||
| DOI | 10.1634/theoncologist.2018-0712 | ||||||||||
| Shelf mark |
|
||||||||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 4845: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MO 494: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.